Interim Director of the Hematology-Oncology Fellowship ProgramUniversity of Illinois at ChicagoChicago, Illinois, United States
Design of the RHEMEDY Study: A Phase 2/3 Safety, Efficacy and Pharmacokinetics Study of CSL889 in Adults and Adolescents with Sickle Cell Disease During Vaso-Occlusive Crisis
Sunday, June 8, 20252:45 PM - 3:00 PM ET